NASDAQ:SPRC SciSparc Q2 2025 Earnings Report $4.64 +0.31 (+7.16%) Closing price 04:00 PM EasternExtended Trading$4.62 -0.02 (-0.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast SciSparc EPS ResultsActual EPS-$27.73Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASciSparc Revenue ResultsActual Revenue$0.23 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASciSparc Announcement DetailsQuarterQ2 2025Date11/18/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile SciSparc Earnings HeadlinesSciSparc Reports Quantum-Enabled Gene Analysis AccelerationOctober 7 at 2:02 PM | rttnews.comSciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 ...October 7 at 2:02 PM | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)SciSparc’s CliniQuantum Hits Quantum-Enabled Breakthrough in Gene Analysis SpeedOctober 7 at 9:30 AM | tipranks.comSciSparc Announces CliniQuantum GPU-Accelerated Quantum Simulation Achieves 16.8-Fold Speedup in Gene-Triplet AnalysisOctober 7 at 8:31 AM | quiverquant.comQSciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum ArchitectureOctober 7 at 8:22 AM | globenewswire.comSee More SciSparc Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SciSparc? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SciSparc and other key companies, straight to your email. Email Address About SciSparcSciSparc (NASDAQ:SPRC) (NASDAQ: SPRC) is an Israel-based specialty pharmaceutical company focused on developing therapies that combine cannabinoids with other pharmaceutical compounds. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including neurological and central nervous system disorders. SciSparc has developed a pipeline that has included SCI-110, an investigational cannabinoid-based treatment being studied for conditions such as Tourette syndrome and Alzheimer’s disease-related agitation, and SCI-210, a combination therapy under development for autism spectrum disorder. The company has also pursued research into cannabinoid-based treatments for pain and other medical conditions. These products remain investigational and are subject to clinical and regulatory requirements. The company was formerly known as Therapix Biosciences Ltd. and adopted the SciSparc name as part of a strategic repositioning of its business. SciSparc is headquartered in Israel and conducts its activities through research, clinical development and collaborations with academic and medical institutions. Its management has included Chief Executive Officer Oz Adler.View SciSparc ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
